Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Daito Pharmaceutical Co., Ltd. ( (JP:4577) ) has provided an announcement.
Daito Pharmaceutical Co., Ltd. announced plans to repurchase and cancel up to 300,000 of its own shares, equivalent to 2.0% of its total issued shares, excluding treasury shares. This move aims to enhance shareholder returns and improve capital efficiency, with the repurchase scheduled from January to May 2025, and cancellation planned for June 2025 following a stock split.
More about Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co., Ltd. operates in the pharmaceutical industry and is listed on the Prime Market of the Tokyo Stock Exchange. The company is focused on enhancing shareholder returns and improving capital efficiency as part of its capital policy under a Medium-term Management Plan.
YTD Price Performance: -3.83%
Average Trading Volume: 24,028
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen30.84B
For an in-depth examination of 4577 stock, go to TipRanks’ Stock Analysis page.
